Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.
Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, Murphy V, Richard D, So AK. Schlesinger N, et al. Among authors: krammer g. Ann Rheum Dis. 2012 Nov;71(11):1839-48. doi: 10.1136/annrheumdis-2011-200908. Epub 2012 May 14. Ann Rheum Dis. 2012. PMID: 22586173 Clinical Trial.
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.
Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, Balfour A, Krammer G, Sallstig P, So A. Schlesinger N, et al. Among authors: krammer g. Ann Rheum Dis. 2011 Jul;70(7):1264-71. doi: 10.1136/ard.2010.144063. Epub 2011 May 3. Ann Rheum Dis. 2011. PMID: 21540198 Free PMC article. Clinical Trial.
Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.
Alten R, Gomez-Reino J, Durez P, Beaulieu A, Sebba A, Krammer G, Preiss R, Arulmani U, Widmer A, Gitton X, Kellner H. Alten R, et al. Among authors: krammer g. BMC Musculoskelet Disord. 2011 Jul 7;12:153. doi: 10.1186/1471-2474-12-153. BMC Musculoskelet Disord. 2011. PMID: 21736751 Free PMC article. Clinical Trial.
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH; TARGET Study Group. Farkouh ME, et al. Among authors: krammer g. Lancet. 2004 Aug 21-27;364(9435):675-84. doi: 10.1016/S0140-6736(04)16894-3. Lancet. 2004. PMID: 15325832 Clinical Trial.
Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial.
Hawkey CJ, Weinstein WM, Stricker K, Murphy V, Richard D, Krammer G, Rebuli R. Hawkey CJ, et al. Among authors: krammer g. Aliment Pharmacol Ther. 2008 May;27(9):838-45. doi: 10.1111/j.1365-2036.2008.03622.x. Epub 2008 Jan 22. Aliment Pharmacol Ther. 2008. PMID: 18221410 Clinical Trial.
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group. Schnitzer TJ, et al. Among authors: krammer g. Lancet. 2004 Aug 21-27;364(9435):665-74. doi: 10.1016/S0140-6736(04)16893-1. Lancet. 2004. PMID: 15325831 Clinical Trial.
100 results